How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Gordon Scott has been an active investor and technical analyst for 20+ years. He is a Chartered Market Technician (CMT). Skylar Clarine is a fact-checker and expert in personal finance with a range of ...

News headlines Recursion Pharmaceuticals reported mixed Q2 2026 results, with revenues dropping significantly while narrowing losses. The company highlighted key milestones in its AI-driven drug ...

Gordon Scott has been an active investor and technical analyst for 20+ years. He is a Chartered Market Technician (CMT). Katrina Ávila Munichiello is an experienced editor, writer, fact-checker, and ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...